Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Sangamo Therapeutics, Inc. (SGMO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.10-0.35 (-4.14%)
At close: 04:00PM EST
8.10 0.00 (0.00%)
After hours: 06:24PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.45
Open8.50
Bid8.04 x 3000
Ask8.35 x 3100
Day's Range8.03 - 8.50
52 Week Range7.81 - 19.43
Volume1,356,130
Avg. Volume1,188,879
Market Cap1.165B
Beta (5Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-0.88
Earnings DateFeb 22, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.67
  • GlobeNewswire

    Organogenesis Appoints Prathyusha Duraibabu to Board of Directors

    CANTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Prathyusha Duraibabu to the Company’s Board of Directors, effective November 19, 2021. Ms. Duraibabu will serve as an independent director of the Company and member of the Audit Co

  • American City Business Journals

    BioMarin says ex-employee downloaded trade secrets. He says it's a misunderstanding.

    The company claims in a lawsuit filed Wednesday that a quality assurance engineer downloaded more than 1,800 documents as he was headed to a competitor on the Peninsula.

  • Business Wire

    Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

    BRISBANE, Calif., November 09, 2021--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences:

Advertisement
Advertisement